natgillin/translations-raw huggingface dataset:
Spørg på apoteket, hvordan du skal bortskaffe medicinrester. 
Ask the medical staff how to throw away medicines you no longer use.
Lægemidler til behandling af depression kaldet monoaminoxidase-hæmmere (MAOI'er). 
- Medicines for the treatment of depression known as Monoamine Oxidase Inhibitors (MAOIs).
Sufentanils gastrointestinale virkning omfatter reduceret motilitet, reduceret sekretion og øget muskeltonus (herunder spasmer) i mave-tarmkanalens sfinctere (se pkt. 
Gastrointestinal effects of sufentanil comprise decreased propulsive motility, reduced secretion and increased muscle tone (up to spasms) of the sphincters of the gastrointestinal tract (see section 4.4).
Patienter bør kun føre motorkøretøj eller betjene maskiner, hvis der er forløbet tilstrækkelig tid efter seneste indgivelse af Zalviso. 
Patients should only drive and use machines if sufficient time has elapsed after the last administration of Zalviso.
Zalviso doseringsudstyret må ikke anvendes, hvis dele af udstyret er synligt beskadiget. 
The Zalviso administration device should not be used if any component is visibly damaged.
Baseret på den populationsfarmakokinetiske analyse af Zalviso hos patienter og raske forsøgspersoner (n = 700), der omfattede 13 patienter med moderat og 6 patienter med svært nedsat leverfunktion, var leverfunktion ikke identificeret som en signifikant covariat for clearance. 
Based on the population pharmacokinetic analysis for Zalviso in patients and healthy volunteers (N = 700), which included 13 patients with moderate and 6 patients with severe hepatic impairment, hepatic function was not identified as a significant covariate for clearance.
- Lægemidler til behandling af depression kaldet serotonin-genoptagelseshæmmere (SSRI'er) og serotonin-noradrenalin-genoptagelseshæmmere (SNRI'er). 
- Medicines for the treatment of depression known as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs).
Analgetiske doser af Zalviso kan hos nogle patienter virke respirationshæmmende i de kliniske forsøg. 
Analgesic doses of Zalviso resulted in respiratory depressive effects in some patients in the clinical trials.
Zalviso er indiceret til behandling af akutte, moderate til svære postoperative smerter hos voksne patienter. 
Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.
Efter enkeltadministration af en 15 mikrogram sufentanil sublingual resoriblet sås middelterminalfasehalveringstider i intervallet 6 til 10 timer. 
After single administration of a 15 micrograms sufentanil sublingual tablet, mean terminal phase halflives in the range of 6 to 10 hours have been observed.
Brug af anden medicin sammen med Zalviso Fortæl det til lægen, hvis du tager anden medicin eller har gjort det for nylig. 
Other medicines and Zalviso Tell your doctor if you are taking, have recently taken or might take any other medicines.
Patienter blev behandlet efter et Zalviso-doseringsskema med 15 mikrogram sufentanil sublingualt efter behov med låst minimum 20 minutters interval i en periode på 72 timer. 
Patients were treated using the Zalviso dosing regimen of 15 micrograms sufentanil sublingually as needed with a minimum 20 minute lock-out interval over a period of 72 hours.
Sufentanil fungerer som en fuld agonist i µ-opioid-receptorer. 
Sufentanil acts as a full agonist in µ-opioid receptors.
Deres hyppigheder blev bestemt ud fra data fra intravenøs administration af sufentanil: almindelig - muskeltrækninger; ikke almindelig - overfølsomhed, apati, nervøsitet, ataksi, dystoni, hyperrefleksi, nedsat hjerterytme og tør hud. 
Their frequencies were established based on data from intravenous administration of sufentanil: common - muscle twitching; uncommon - hypersensitivity, apathy, nervousness, ataxia, dystonia, hyperreflexia, heart rate decreased and dry skin.
Symptomerne på overdosering af sufentanil er en forstærkning af den farmakologiske virkning. 
Sufentanil overdose is manifested by an exaggeration of its pharmacological effects.
Patienter med nedsat respirationsfunktion eller respiratorisk reserve har højere risiko. 
Patients at higher risk are those with respiratory impairment or reduced respiratory reserve.
Samtidig administration af sufentanil og et serotonergt middel som f.eks. selektive serotoningenoptagelseshæmmere (SSRI'er), serotonin-noradrenalinin-genoptagelseshæmmere (SNRI'er) eller monoaminoxidase-hæmmere (MAOI'er) kan øge risikoen for serotoninsyndrom, som er en potentielt livstruende tilstand. 
Co-administration of sufentanil with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), or Monoamine Oxidase Inhibitors (MAOIs), may increase the risk of serotonin syndrome, a potentially life threatening condition.
Apati* Nervøsitet* 
Confusional state Apathy* Nervousness*
En populationsfarmakokinetisk analyse af plasmasufentanil-koncentrationer efter brug af Zalviso hos patienter og raske forsøgspersoner (n = 700), der omfattede 75 patienter med moderat og 7 patienter med svært nedsat nyrefunktion, identificerede ikke nyrefunktion som en signifikant covariat for clearance. 
A population pharmacokinetic analysis of plasma sufentanil concentrations following usage of Zalviso in patients and healthy volunteers (N = 700), which included 75 patients with moderate and 7 patients with severe renal impairment, did not identify renal function as a significant covariate for clearance.
Zalviso skal administreres med forsigtighed til patienter med moderat til svært nedsat lever- eller nyrefunktion (se afsnit 4.4). 
Zalviso should be administered with caution to patients with moderate to severe hepatic or severe renal impairment (see section 4.4).
Det anbefales at undlade at amme under behandling med sufentanil på grund af risiko for opioid virkning eller toksicitet hos den ammede nyfødte/spædbarnet (se pkt. 
Breastfeeding is not recommended when sufentanil is administered, due to the risk of opioid effects or toxicity in the breastfed newborns/infants (see section 4.9).
6.6 for instruktioner i opsætning og håndtering af Zalviso doseringsudstyr før administration. 
For instructions on the setup and handling of the Zalviso administration device before administration, see section 6.6.
Efter behandlingen tager sundhedspersonalet Zalviso doseringsudstyret og bortskaffer eventuelle ubrugte resoribletter. 
After your treatment the medical staff will take the Zalviso administration device and dispose of any unused tablets accordingly.
Samtidig brug af sedativa, herunder barbiturater, neuroleptika eller andre opioider, halogengasser eller andre ikke-selektive sedativa (f.eks. alkohol) kan forstærke en hæmmet respiration. 
The concomitant use of CNS depressants including barbiturates, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.
Du bør kun føre motorkøretøj eller betjene maskiner, hvis der er forløbet tilstrækkelig lang tid efter seneste dosis Zalviso. 
You should only drive and use machines if sufficient time as elapsed after your last dose of Zalviso.
Sekundær farmakodynamisk virkning 
Secondary pharmacodynamics effects
På grund af det begrænsede antal undersøgte patienter med svært nedsat nyrefunktion skal Zalviso dog anvendes med forsigtighed hos sådanne patienter (se pkt. 
However, due to the limited number of patients with severe renal impairment studied, Zalviso should be used with caution in such patients (see section 4.4).
Hyppighed ikke kendt (hyppighed kan ikke estimeres ud fra forhåndenværende data): svære allergiske reaktioner (anafylaktisk shock), krampeanfald (anfald), koma, små pupiller, rødme af huden, abstinenssyndrom. 
Frequency not known (frequency cannot be estimated from the available data): severe allergic reactions (anaphylactic shock), convulsion (fits), coma, small pupil size, redness of the skin, withdrawal syndrome.
Zalviso sublinguale resoribletter indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. lægemidlet er i det væsentlige natrium-frit. 
Zalviso sublingual tablets contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium free'.
Doseringsudstyret må ikke anvendes, hvis dele er synligt beskadiget. 
Do not use the device if any component is visibly damaged.
Må kun anvendes sammen med Zalviso doseringsudstyr. 
To be used only with the Zalviso administration device.
Sådan skal du tage Zalviso 
How to take Zalviso
Zalviso sublinguale resoribletter, 3 mm i diameter, er orangefarvede resoribletter med flad overside og afrundede kanter. 
Zalviso sublingual tablets of 3 mm diameter are orange-coloured flat-faced tablets with rounded edges.
Gentagen dosistoksicitet 
Repeat-dose toxicity
Risiko forbundet med samtidig brug af sedativa såsom benzodiazepiner eller lignende stoffer. 
Risk from concomitant use of sedating medicinal products such as benzodiazepines or related substances
Primær farmakodynamisk virkning 
Primary pharmacodynamics effects
Sufentanil metaboliseres primært af det humane cytokrom P450-3A4-enzym. 
Sufentanil is primarily metabolised by the human cytochrome P450-3A4 enzyme.
Patienter med moderat til svært nedsat leverfunktion eller svært nedsat nyrefunktion skal nøje overvåges for symptomer på en overdosis af sufentanil (se pkt. 
Patients with moderate to severe hepatic or severe renal impairment should be monitored carefully for symptoms of sufentanil overdose (see section 4.9).
Sufentanil kan bevirke, at det kliniske forløb for en patient med kranietraume bliver uklart. 
Sufentanil may obscure the clinical course of patients with head injury.
Den alvorligste bivirkning af sufentanil er hæmmet respiration, der potentielt kan føre til apnø og åndedrætsstop (se pkt. 
The most serious adverse reaction of sufentanil is respiratory depression, potentially leading to apnoea and respiratory arrest (see section 4.4).
Croscarmellosenatrium Stearinsyre 
Croscarmellose sodium Stearic acid
Sublingual anvendelse. 
Sublingual use.
Ikke almindelige bivirkninger (forekommer hos op til 1 ud af 100): allergiske reaktioner, manglende interesse eller følelser, nervøsitet, søvnløshed, unormale fornemmelser i huden, problemer med at koordinere muskelbevægelser, muskelsammentrækninger, overdrevne reflekser, synsforstyrrelser, nedsat hjerterytme, mundtørhed, øget sved produktion, udslæt, tør hud, kulderystelser, svækkelse. 
Uncommon side effects (may affect up to 1 in 100 people): allergic reactions, lack of interest or emotion, nervousness, sleepiness, abnormal sensation of the skin, problems coordinating muscle movements, muscle contractions, exaggeration of reflexes, vision disturbances, decreased heart rate, dry mouth, excessive sweating, rash, dry skin, chills, weakness.
Zalviso 15 mikrogram resoribletter, sublinguale Sufentanil 
Zalviso 15 micrograms sublingual tablets Sufentanil
VIDENSKABELIGE KONKLUSIONER OG BEGRUNDELSER FOR ÆNDRING AF BETINGELSERNE FOR MARKEDSFØRINGSTILLADELSEN/-TILLADELSERNE 
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
Zalviso sublinguale resoribletter skal egenadministreres med Zalviso doseringsudstyr, som kun må aktiveres af patienten som respons på smerte (se pkt. 
The Zalviso sublingual tablets are to be self-administered using the Zalviso administration device which should only be actuated by the patient in response to pain (see section 6.6).
Zalviso bør ikke anvendes under graviditet og til kvinder i den fertile alder, som ikke anvender sikker prævention. 
Zalviso is not recommended during pregnancy and in women of childbearing potential not using contraception.
≥1/10.000 til <1/1.000 Meget sjælden <1/10.000 Ikke kendt 
Uncommon ≥1/1,000 and <1/100 Rare
Zalviso må kun administreres i hospitalsregie. 
Zalviso is to be administered in a hospital setting only.
EU/1/15/1042/001 1 patron a 40 sublinguale resoribletter EU/1/15/1042/002 10 patroner a 40 sublinguale resoribletter EU/1/15/1042/003 20 patroner a 40 sublinguale resoribletter 
EU/1/15/1042/001 1 cartridge of 40 sublingual tablets EU/1/15/1042/002 10 cartridges of 40 sublingual tablets each EU/1/15/1042/003 20 cartridges of 40 sublingual tablets each
Zalviso 15 mikrogram resoribletter, sublinguale 
Zalviso 15 micrograms sublingual tablets
Hæmmet respiration forårsaget af sufentanil er reversibelt med opioidantagonister. 
Respiratory depression caused by sufentanil can be reversed by opioid antagonists.
Sufentanil kan som µ-opioid receptoragonist nedsætte den gastrointestinale motilitet. 
Sufentanil as a µ-opioid receptor agonist may slow the gastrointestinal motility.
De sublinguale resoribletter leveres i patroner, som hver indeholder 40 sublinguale resoribletter. 
The sublingual tablets are supplied in cartridges; each cartridge contains 40 sublingual tablets.
Samtidig brug af Zalviso og sedativa såsom benzodiazepiner eller lignende stoffer, kan føre til sedation, respirationsdepression, koma og dødsfald. 
Concomitant use of Zalviso and sedating medicinal products such as benzodiazepines or related substances may result in sedation, respiratory depression, coma and death.
Sufentanil metaboliseres hos mennesker primært af cytokrom P450-3A4-enzymsystemet (se pkt. 
Sufentanil is mainly metabolised in humans by the cytochrome P450-3A4 enzyme system (see section 4.5).
Svimmelhed Hovedpine Sedation 
Dizziness Headache Sedation
Der er gennemført to studier af lokal tolerance af sufentanil sublinguale resoribletter i hamsteres kindposer. 
Two local tolerance studies were conducted in the hamster cheek pouch with the sufentanil sublingual tablets.
10 patroner med hver 40 sublinguale resoribletter 20 patroner med hver 40 sublinguale resoribletter 
1 cartridge of 40 sublingual tablets 10 cartridges of 40 sublingual tablets each 20 cartridges of 40 sublingual tablets each
EU/1/15/1042/004 2 x 20 patroner a 40 sublinguale resoribletter EU/1/15/1042/005 3 x 20 patroner a 40 sublinguale resoribletter EU/1/15/1042/006 5 x 20 patroner a 40 sublinguale resoribletter 
EU/1/15/1042/004 2 x 20 cartridges of 40 sublingual tablets each EU/1/15/1042/005 3 x 20 cartridges of 40 sublingual tablets each EU/1/15/1042/006 5 x 20 cartridges of 40 sublingual tablets each
BILAG IV 
Annex IV
Samtidig brug af Zalviso med sedativa såsom benzodiazepiner eller lignende stoffer øger risikoen for sedation, respirationsdepression, koma og dødsfald på grund af den additive CNS-hæmmende virkning. 
The concomitant use of opioids with sedating medicinal products such as benzodiazepines or related substances increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect.
Når patronen er taget ud af posen, skal den omgående placeres i Zalviso doseringsudstyret. 
After removing from the sachet, the cartridge should be placed into the Zalviso administration device immediately.
Maksimale koncentrationer af sufentanil nås cirka 50 minutter efter en enkelt dosis. 
Maximum concentrations of sufentanil are achieved approximately 50 minutes after a single dose; this is shortened to approximately 20 minutes following repeat dosing.
Der er ikke gennemført særlige populationsstudier med sufentanil sublinguale resoribletter hos patienter med nedsat lever- eller nyrefunktion. 
No special population studies were performed using sufentanil sublingual tablets in hepatic and renal impaired patients.
Tilsvarende CST½-værdier sås efter både enkelt og gentagen administration. 
Similar CST½ values were observed following both single and repeated administration demonstrating that there is a predictable and consistent duration of action after multiple dosing of the sublingual tablet.
Sådan tager du de sublinguale resoribletter med doseringsudstyret Før du begynder at tage Zalviso, viser din læge eller sygeplejerske dig, hvordan du skal bruge Zalviso doseringsudstyret. 
Before you start using Zalviso, your doctor or nurse will show you how to use the Zalviso administration device.
Der er ikke gennemført særlige populationsstudier med sufentanil sublinguale resoribletter hos ældre. 
No special population studies were performed using sufentanil sublingual tablets in elderly patients.
Serotonerge mideler 
Serotonergic agents
Derfor skal Zalviso anvendes med forsigtighed hos disse patienter (se pkt. 
Therefore, Zalviso should be used with caution in such patients (see section 4.4).
Sufentanil kan som µ-opioid receptoragonist forårsage spasme i sfincter Oddi. 
Sufentanil as a µ-opioid receptor agonist may cause spasm of the sphincter of Oddi.
Åndedrætsstop 
Respiratory arrest
Samtidig brug af Zalviso og beroligende medicin såsom benzodiazepiner eller lignende medicin øger risikoen for døsighed, vejrtrækningsbesvær (respirationsdepression), koma og kan være livstruende. 
Concomitant use of Zalviso and sedating medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening.
Konstipation Dyspepsi 
Constipation Dyspepsia
Indeholder sunset yellow FCF aluminium lake (E110), indeholder natrium. 
Contains sunset yellow FCF Aluminium Lake (E110), contains sodium.
Grünenthal Norway AS C.J. Hambros Plass 2C N-0164 Oslo Tlf: +47 22996054 
Grünenthal Norway AS C.J. Hambros Plass 2C 0164 Oslo
Sufentanil bør anvendes med forsigtighed af patienter, som kan være særligt modtagelige for cerebrale virkninger af CO2-retention. 
Sufentanil should be used with caution in patients who may be particularly susceptible to the cerebral effects of CO2 retention, such as those with evidence of increased intracranial pressure or impaired consciousness.
Når patienter titrerede sig selv til analgetisk virkning med Zalviso, nåede sufentanils plasmakoncentrationer gennemsnitligt 60-100 pg/ml efter to dages brug. 
When patients titrated themselves to analgesic effect with Zalviso, plasma sufentanil concentrations averaged 60-100 pg/ml over two days of use, with no effect based on age or body mass index (BMI), or mild to moderate renal or liver impairment.
Zalviso må kun tages i et medicinsk overvåget miljø. 
Zalviso is only to be taken in a hospital setting.
Hjælpestof(fer), som behandleren skal være opmærksom på Hver sublingual resoriblet indeholder 0,074 mg sunset yellow FCF aluminium lake (E110). 
Each sublingual tablet contains 0.074 mg sunset yellow FCF Aluminium Lake (E110).
Zalviso sublinguale resoribletter indeholder azo-farvestoffet sunset yellow FCF aluminium lake (E110), som kan forårsage allergiske reaktioner. 
Zalviso sublingual tablets contain the azo colouring agent sunset yellow FCF Aluminium Lake (E110), which may cause allergic reactions.
Zalviso sublinguale resoribletter fås i pakningsstørrelser med 1, 10 og 20 patroner og i multipakninger med 40 (2 pakninger a 20), 60 (3 pakninger a 20) og 100 (5 pakninger a 20) patroner, svarende til henholdsvis 40, 400, 800, 1600, 2400 og 4000 sublinguale resoribletter. 
Zalviso sublingual tablets are available in pack sizes of 1, 10 and 20 cartridges and in multipacks containing 40 (2 packs of 20), 60 (3 packs of 20) and 100 (5 packs of 20) cartridges, equivalent to 40, 400, 800, 1,600, 2,400 and 4,000 sublingual tablets, respectively.
Zalviso sublinguale resoribletter er orangefarvede resoribletter med flad overside og afrundede kanter. 
What Zalviso looks like and contents of the pack Zalviso sublingual tablets are orange-coloured flat-faced tablets with rounded edges.
Hæmmet respiration 
Respiratory depression
1 patron a 40 sublinguale resoribletter 
1 cartridge of 40 sublingual tablets
Zalviso fås i pakningsstørrelser med 1 og 10, 20 patroner og multipakninger med 40 (2 pakninger a 20), 60 (3 pakninger a 20) og 100 (5 pakninger a 20) patroner, svarende til henholdsvis 40, 400, 800, 1600, 2400 og 4000 sublinguale resoribletter. 
Zalviso is available in pack sizes of 1 and 10, 20 cartridges and multipacks containing 40 (2 packs of 20), 60 (3 packs of 20) and 100 (5 packs of 20) cartridges, equivalent to 40, 400, 800, 1,600, 2,400 and 4,000 sublingual tablets, respectively.
Sufentanil udskilles i modermælk og kan give bivirkninger hos det ammede barn. 
Sufentanil passes into breast milk and can cause side effects in the breast-fed child. Breastfeeding is not recommended when you take Zalviso.
Tlf.: +49-241-569-0 
Tel.: +49-241-569-0
Spørg lægen eller sundhedspersonalet, hvis der er noget, du er i tvivl om. 
Check with your doctor if you are not sure.
Sufentanil udskilles i human mælk, når det gives intravenøst. 
Sufentanil is excreted in human milk when applied intravenously; therefore caution is advised when Zalviso is administered to breast-feeding women.
Hvis du har taget for mange Zalviso 
If you take more Zalviso than you should
Hyppigheden er defineret som følger: Meget almindelig ≥1/10 Almindelig ≥1/100 til <1/10 Ikke almindelig ≥1/1.000 til <1/100 Sjælden 
Very common ≥1/10 Common
Almindelige bivirkninger (forekommer hos op til 1 ud af 10 personer): forvirring, svimmelhed, hovedpine, døsighed, øget hjerterytme, højt blodtryk, lavt blodtryk, forstoppelse, fordøjelsesbesvær, hudkløe, ufrivillige muskelkramper, muskelsammentrækninger, vandladningsbesvær. 
confusion, dizziness, headache, drowsiness, increased heart rate, high blood pressure, low blood pressure, constipation, indigestion, itching of the skin, involuntary muscle cramps, muscle twitching, difficulty passing urine.
Sufentanil kan forårsage hæmmet respiration (se pkt. 
Sufentanil may cause respiratory depression (see section 4.4) and also suppresses the cough reflex.
Muskelspasmer Muskeltrækninger* 
Involuntary muscle spasms
800 sublinguale resoribletter (20 patroner a 40 sublinguale resoribletter) Del af multipakning, må ikke sælges separat. 
800 sublingual tablets (20 cartridges of 40 sublingual tablets each).
Patienten skal ved smerter egenadministrere Zalviso sublinguale resoribletter med Zalviso doseringsudstyr. 
Zalviso sublingual tablets are to be self-administered by the patient in response to pain using the Zalviso administration device.
EU/1/15/1042/001 EU/1/15/1042/002 EU/1/15/1042/003 EU/1/15/1042/004 EU/1/15/1042/005 EU/1/15/1042/006 
EU/1/15/1042/006
Multipakning: 1600 sublinguale resoribletter [40 (2 pakninger a 20) patroner a 40 sublinguale resoribletter] 
Multipack: 1600 sublingual tablets [40 (2 packs of 20) cartridges of 40 sublingual tablets each] Multipack: 2400 sublingual tablets [60 (3 packs of 20) cartridges of 40 sublingual tablets each] Multipack: 4000 sublingual tablets [100 (5 packs of 20) cartridges of 40 sublingual tablets each]
Deutschland Grünenthal GmbH Zieglerstraße 6 
Deutschland Grünenthal GmbH Zieglerstr.
Resoribletten må ikke knuses, tygges eller synkes. 
Do not crush, chew, or swallow the tablet.
Sufentanil kan forårsage dosisafhængig respirationshæmning. 
Sufentanil may cause respiratory depression, for which the degree/severity is dose related.
Hver patron ligger i en pose med en iltabsorber. 
One cartridge is packed in a sachet including an oxygen absorber.
Er du i tvivl, så spørg lægen. 
- If you have any further questions, ask your doctor or nurse.
Synsforstyrrelser Miose 
Miosis disturbances
Mundtørhed 
Excipients
Amning 
Apnoea
Nyrer og urinveje 
Nausea Vomiting
Det skal du vide, før du begynder at tage Zalviso Sådan skal du tage Zalviso Bivirkninger 
What Zalviso is and what it is used for What you need to know before you take Zalviso How to take Zalviso
Abstinenssyndrom 
Hyperhidrosis Rash
Dato for første markedsføringstilladelse: 12. maj 2016 
Date of first authorisation: 12 May 2016
Relevansen for mennesker er ukendt. 
The relevance for humans is not known.
Ikke alle ender med at få den samme vedligeholdelsesdosis. 
Not everyone will end up on the same maintenance dose.
Der var ingen signifikant behandlingsvirkning fra baseline til uge 26. 
There was no significant treatment effect from baseline to Week 26.
Uptravi kan anvendes alene, hvis patienten ikke er kandidat til disse lægemidler. 
Uptravi can be used on its own if the patient is not a candidate for these medicines.
• Myokardieinfarkt inden for de sidste 6 måneder. 
• Myocardial infarction within the last 6 months.
Eksponeringen for selexipag var op til 4,2 år. 
The exposure to selexipag was up to 4.2 years.
Hver patient med PAH er forskellig. 
Every patient with PAH is different.